JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Italy Fines Apple €98.6 Million Over App Store Dominance 
BURLINGTON, Mass., Feb. 07, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2016 financial results on Tuesday, February 21, 2017, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by dialing 844-239-5284 (+1-512-961-6497 for international callers), passcode 66556990. The call can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. Steven Chehames Investor Relations +1-781-425-1659 [email protected] http://www.lemaitre.com
